The Role of Mpl and Imiquimod Adjuvants in Enhancement of Immune Response and Protection in Balb/C Mice Immunized With Soluble Leishmania Antigen (Sla) Encapsulated in Nanoliposome Publisher Pubmed



Emami T^{1, 2} ; Rezayat SM¹ ; Khamesipour A³ ; Madani R² ; Habibi G⁴ ; Hojatizade M⁵ ; Jaafari MR^{6, 7}
Source: Artificial Cells# Nanomedicine and Biotechnology Published:2018

Abstract

Adjuvants play an essential role in the induction of immunity against leishmaniasis. In this study, monophosphoryl lipid A (MPL) and imiquimod (IMQ) were used as TLR ligands adjuvants to enhance immunogenicity and rate of protection against leishmaniasis. Nanoliposomes containing soluble Leishmania antigens (SLA) and adjuvants were consisted of DSPC, DSPG and Chol prepared by using lipid film method followed by bath sonication. The size of nanoliposomes was around 95 nm and their zeta potential was negative. BALB/c mice were immunized by liposomal formulations of lip/SLA, lip/MPL/SLA, lip/IMQ/SLA, lip/MPL/IMQ/SLA, lip/SLA + lip/IMQ, lip/SLA + lip/MPL, lip/SLA + lip/MPL/IMQ and five controls of SLA, lip/MPL, lip/IMQ, lip/MPL/IMQ and buffer by subcutaneously (SC) injections, three times in 2 weeks intervals. The synergic effect of two adjuvants when they are used in one formulation showed significantly (p <.001) smaller footpad swelling and the lowest parasite burden in lymph node and foot after the challenge. IgG2a in these groups showed the higher titre compared to control groups, which is compatible with the high IFN-γ production and lowest IL-4. Taken together the results indicated that co-delivery of MPL and IMQ adjuvants and antigen in nanoliposome carrier could be an appropriate delivery system to induce cellular immunity pathway against leishmaniasis. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.